Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL: Aflibercept for Neovascular AMD
NCT02441816Phase 4Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Nov 2014
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Moorfields Eye Hospital. Primary endpoint: Mean change in visual acuity (Early Treatment of Diabetic Retinopathy Study letter score) at 24 months. Started Nov 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02441816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441816.